2. Signaling Pathways
  3. Immunology/Inflammation
  4. LAG-3

LAG-3

Lymphocyte activation gene-3; CD223

Lymphocyte activation gene-3 (LAG-3) is an immune checkpoint protein that belongs to the immunoglobulin superfamily. LAG-3 is mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells. LAG-3 has a high affinity for MHC class II molecules and can also bind to FGL1. Binding of LAG-3 to its ligands leads to the inhibition of T cell activation and proliferation, thereby regulating the immune response. In the tumor microenvironment, overexpression of LAG-3 is often observed, which helps tumor cells escape immune surveillance. LAG-3 is considered as an important target for cancer immunotherapy. In addition to its role in tumor immunity, LAG-3 is also involved in the pathogenesis of some autoimmune diseases and infectious diseases[1][2][3].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99156
    Relatlimab
    		98.00%
    Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer.
    Relatlimab
  • HY-P99141
    Anti-Mouse LAG-3 Antibody (C9B7W)
    		Inhibitor 99%
    Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4+ T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC).
    Anti-Mouse LAG-3 Antibody (C9B7W)
  • HY-108691
    PF-06465469
    		Inhibitor 99.48%
    PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma.
    PF-06465469
  • HY-144987
    RBN013209
    		Inhibitor 98.63%
    RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors.
    RBN013209
  • HY-P991301
    IMP-761
    		Inhibitor
    IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
    IMP-761
  • HY-122081
    CPI-644
    		Inhibitor
    CPI-644 is a selective EP300/CBP bromodomain inhibitor, with an IC50 of 0.18 µM against the CBP bromodomain. CPI-644 reduces the proportion of FOXP3+ cells and downregulates the expression of LAG-3, CTLA-4 and PD-1. CPI-644 can be used in cancer-related research.
    CPI-644
  • HY-P992156
    Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853)
    		Inhibitor
    Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) is a monoclonal antibody that specifically binds to human, mouse and bovine LAG-3. Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) can be used in the research of colon cancer, colorectal cancer and rectal cancer.
    Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853)
  • HY-181685
    LAGi-DEL
    		Inhibitor
    LAGi-DEL is a LAG-3 inhibitor, with Kd values of 97.33 nM and 271 nM in surface plasmon resonance (SPR) assay and microscale thermophoresis (MST) assay, respectively. LAGi-DEL blocks the LAG-3/MHC-II interaction, with an EC50 of 138 nM. LAGi-DEL restores T cell activation, enhances IFN-γ secretion and promotes immune-mediated cytotoxicity. LAGi-DEL can be used in the research of acute myeloid leukemia, lung cancer and melanoma.
    LAGi-DEL
  • HY-P99613
    Favezelimab
    Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma. For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Favezelimab
  • HY-P99573
    Tebotelimab
    		99.52%
    Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity.
    Tebotelimab
  • HY-P99617
    Fianlimab
    		99.04%
    Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity.
    Fianlimab
  • HY-P99027
    Ieramilimab
    		≥99.0%
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors.
    Ieramilimab
  • HY-P99922
    Encelimab
    		Inhibitor
    Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft).
    Encelimab
  • HY-P990750
    Negalstobart
    Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Negalstobart
  • HY-P990976
    Brivestobart
    		98.791%
    HY-P990976 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Brivestobart
  • HY-P99736
    Miptenalimab
    Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II.
    Miptenalimab
  • HY-P990700
    Tobemstomig
    Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Tobemstomig
  • HY-176813
    LAG-3 Hit II
    		Inhibitor 99.58%
    LAG-3 Hit II is a LAG-3 inhibitor with a KD of 4.32  μM. LAG-3 Hit II can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research.
    LAG-3 Hit II
  • HY-P990046
    Tuparstobart
    Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells.
    Tuparstobart
  • HY-P990968
    Alcestobart
    		98.383%
    HY-P990968 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Alcestobart
Cat. No. Product Name / Synonyms Application Reactivity